Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma (Nasdaq: ZBIO) has announced key inducement grants for two newly appointed executives. The company's Compensation Committee approved non-qualified stock options on April 15, 2025, as part of their employment agreements.
Dr. Lisa von Moltke, appointed as Head of Research and Development and Chief Medical Officer, received options to purchase 400,000 shares. Dr. Haley Laken, the new Chief Scientific Officer, received options for 250,000 shares.
Both grants have a ten-year term with an exercise price of $8.72 per share, matching Zenas' closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year of employment and the remainder vesting in 36 monthly installments, contingent on continued service.
Zenas BioPharma (Nasdaq: ZBIO) ha annunciato importanti concessioni di incentivi per due nuovi dirigenti nominati. Il Comitato per la Remunerazione della società ha approvato opzioni azionarie non qualificate il 15 aprile 2025, come parte degli accordi di lavoro.
La Dott.ssa Lisa von Moltke, nominata Responsabile della Ricerca e Sviluppo e Chief Medical Officer, ha ricevuto opzioni per l'acquisto di 400.000 azioni. La Dott.ssa Haley Laken, nuova Chief Scientific Officer, ha ottenuto opzioni per 250.000 azioni.
Entrambe le concessioni hanno una durata di dieci anni con un prezzo di esercizio di 8,72 $ per azione, corrispondente al prezzo di chiusura delle azioni Zenas alla data della concessione. Le opzioni matureranno in quattro anni, con il 25% che matura dopo un anno di servizio e il resto che matura in 36 rate mensili, subordinatamente alla continuazione del rapporto di lavoro.
Zenas BioPharma (Nasdaq: ZBIO) ha anunciado concesiones clave de incentivos para dos ejecutivos recientemente nombrados. El Comité de Compensación de la empresa aprobó opciones sobre acciones no calificadas el 15 de abril de 2025, como parte de sus acuerdos laborales.
La Dra. Lisa von Moltke, nombrada Jefa de Investigación y Desarrollo y Directora Médica, recibió opciones para comprar 400,000 acciones. La Dra. Haley Laken, la nueva Directora Científica, recibió opciones para 250,000 acciones.
Ambas concesiones tienen un plazo de diez años con un precio de ejercicio de $8.72 por acción, igualando el precio de cierre de las acciones de Zenas en la fecha de concesión. Las opciones se otorgarán durante cuatro años, con un 25% que se consolida tras un año de empleo y el resto en 36 cuotas mensuales, condicionadas a la continuidad del servicio.
Zenas BioPharma (나스닥: ZBIO)는 새로 임명된 두 임원에 대한 주요 유인 보조금(inducement grants)을 발표했습니다. 회사의 보상 위원회는 2025년 4월 15일 고용 계약의 일환으로 비자격 스톡 옵션을 승인했습니다.
연구개발 책임자 겸 최고 의료 책임자로 임명된 Dr. Lisa von Moltke는 400,000주 매수 옵션을 받았습니다. 신임 최고 과학 책임자인 Dr. Haley Laken은 250,000주 옵션을 받았습니다.
두 보조금 모두 10년 만기이며, 행사 가격은 부여일 기준 Zenas 주식 종가인 $8.72입니다. 옵션은 4년에 걸쳐 베스팅되며, 1년 근무 후 25%가 베스팅되고 나머지는 36개월간 매월 균등 분할 베스팅되며 지속적인 근무가 조건입니다.
Zenas BioPharma (Nasdaq : ZBIO) a annoncé des attributions incitatives clés pour deux cadres récemment nommés. Le comité de rémunération de la société a approuvé des options d'achat d'actions non qualifiées le 15 avril 2025, dans le cadre de leurs contrats de travail.
La Dre Lisa von Moltke, nommée responsable de la recherche et développement et directrice médicale, a reçu des options pour acheter 400 000 actions. La Dre Haley Laken, nouvelle directrice scientifique, a reçu des options pour 250 000 actions.
Les deux attributions ont une durée de dix ans avec un prix d'exercice de 8,72 $ par action, correspondant au cours de clôture des actions Zenas à la date d'attribution. Les options seront acquises sur quatre ans, avec 25 % acquis après un an d'emploi et le reste acquis en 36 versements mensuels, sous réserve de la poursuite du service.
Zenas BioPharma (Nasdaq: ZBIO) hat wichtige Anreizzuteilungen für zwei neu ernannte Führungskräfte bekannt gegeben. Der Vergütungsausschuss des Unternehmens genehmigte am 15. April 2025 nicht qualifizierte Aktienoptionen im Rahmen ihrer Arbeitsverträge.
Dr. Lisa von Moltke, die zur Leiterin für Forschung und Entwicklung sowie Chief Medical Officer ernannt wurde, erhielt Optionen zum Kauf von 400.000 Aktien. Dr. Haley Laken, die neue Chief Scientific Officer, erhielt Optionen für 250.000 Aktien.
Beide Zuteilungen haben eine zehnjährige Laufzeit mit einem Ausübungspreis von 8,72 $ pro Aktie, entsprechend dem Schlusskurs der Zenas-Aktie am Zuteilungsdatum. Die Optionen werden über vier Jahre vesten, wobei 25 % nach einem Jahr Beschäftigung vesten und der Rest in 36 monatlichen Raten, abhängig vom fortdauernden Dienstverhältnis.
- Strategic strengthening of executive team with two key appointments in R&D leadership
- Structured compensation plan aligning executive interests with long-term shareholder value
- Potential future dilution from 650,000 new stock options
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors (the “Committee”) granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).
The Committee granted a non-qualified stock option to purchase 400,000 shares of the Company’s common stock to Lisa von Moltke, M.D., who was recently appointed to the role of Head of Research and Development and Chief Medical Officer (the “CMO Inducement Grant”). In addition, the Committee granted a non-qualified stock option to purchase 250,000 shares of the Company’s common stock to Haley Laken, Ph.D., the Company’s new Chief Scientific Officer (the “CSO Inducement Grant”).
The CMO Inducement Grant and the CSO Inducement Grant (the “Grants”) each have a ten-year term and an exercise price per share of
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
FAQ
What are the terms of ZBIO's new stock option grants announced in April 2025?
How will the stock options vest for ZBIO's new executives?
What was the exercise price for ZBIO's inducement grants issued in April 2025?
Who are the new executives receiving ZBIO's inducement grants?
